Effectiveness and safety of drugs for obesity

Kristina Henderson Lewis,Caroline E Sloan,Daniel H Bessesen,David Arterburn

DOI: https://doi.org/10.1136/bmj-2022-072686

2024-03-25

BMJ

Abstract:Abstract Recent publicity around the use of new antiobesity medications (AOMs) has focused the attention of patients and healthcare providers on the role of pharmacotherapy in the treatment of obesity. Newer drug treatments have shown greater efficacy and safety compared with older drug treatments, yet access to these drug treatments is limited by providers’ discomfort in prescribing, bias, and stigma around obesity, as well as by the lack of insurance coverage. Now more than ever, healthcare providers must be able to discuss the risks and benefits of the full range of antiobesity medications available to patients, and to incorporate both guideline based advice and emerging real world clinical evidence into daily clinical practice. The tremendous variability in response to antiobesity medications means that clinicians need to use a flexible approach that takes advantage of specific features of the antiobesity medication selected to provide the best option for individual patients. Future research is needed on how best to use available drug treatments in real world practice settings, the potential role of combination therapies, and the cost effectiveness of antiobesity medications. Several new drug treatments are being evaluated in ongoing clinical trials, suggesting that the future for pharmacotherapy of obesity is bright.

medicine, general & internal

What problem does this paper attempt to address?

This paper mainly discusses the effectiveness and safety of obesity drugs and their impact on health outcomes. With the increasing prevalence of obesity, although there are limitations to using BMI as a measure of obesity, BMI≥30 is associated with an increased risk of various complications, including type 2 diabetes, hypertension, and joint diseases. The paper points out that obesity is now recognized as a chronic relapsing disease that requires long-term treatment, including the use of anti-obesity drugs.

The article summarizes the latest guidelines, systematic reviews, randomized controlled trials, and observational studies to guide clinicians in considering the safety and effectiveness of anti-obesity drugs in their decision-making. Despite the better efficacy and safety of newer drugs, their prescription rates remain low, partly due to prescribers' concerns, bias against obesity, high costs, and insufficient insurance coverage. The paper also emphasizes individual differences in drug response and provides discussion points on how to select the best drug based on patient needs.

The paper also lists the anti-obesity drugs approved by the FDA in the United States, including their mechanisms of action, side effects, costs, and practical considerations. Finally, the article mentions non-FDA approved drugs that are available for weight loss, such as metformin and sodium-glucose co-transporter 2 inhibitors, and discusses their usage and potential effects.

In conclusion, this paper aims to help physicians better understand and utilize anti-obesity drugs to improve the clinical practice of obesity treatment and identifies key areas for future research, including real-world drug applications, cost-effectiveness analysis of combination therapy, and progress in clinical trials of new drugs.